Magellan BioScience Group, Inc. Awarded SBIR Grant for anti-Malarial Drug Discovery Collaboration with University of South Florida
Tampa, FL, July 06, 2007 --(PR.com)-- Magellan BioScience Group, Inc. (Magellan), a pioneer in innovative drug discovery and development from marine microbial sources, and the University of South Florida (USF) announced today that they have been awarded a Phase I Small Business Innovative Research Grant (SBIR) from the National Institute of Health (NIH) and matching funds from the Florida High Tech Corridor Council totaling more than $350,000. Magellan will team with USF scientists Drs. Dennis Kyle and Alberto Van Olphen of the Department of Global Health, College of Public Health, and Dr. Bill Baker of the Department of Chemistry, College of Arts and Sciences. The grants will support a multidisciplinary drug discovery collaboration to identify novel anti-malarial drugs from Magellan’s and Dr. Baker’s diverse marine microbial collections.
This collaboration will bring together Magellan’s unique collection of marine-derived microorganisms and their natural product chemistry expertise with Dr. Kyle’s anti-malaria screening technologies, and Dr. Baker’s natural product discovery expertise. The Magellan-USF team will characterize lead candidates from Magellan’s collection by using bioassays and will optimize novel chemicals into preclinical drug candidates. Magellan’s expertise in various chemistry technologies will stimulate and accelerate early discovery efforts.
“We are excited to initiate this drug discovery collaboration with the University of South Florida that will further validate our capabilities as a provider of novel small molecules and develop Magellan into a preferred First Class Drug Discovery Company,” said Dr. Todd R. Daviau, CEO of Magellan. “USF’s scientific and technological approach powered by their highly qualified and organized research team constitutes a significant opportunity for the discovery and development of new anti-malaria candidates.”
“Malaria is a major public health threat, with over 2 million children dying of the disease every year in Africa,” said Dr. Dennis Kyle, Professor of Global Health. “New drugs are urgently needed to combat multi-drug resistant malaria.”
About Magellan:
Magellan BioScience Group, Inc., based in Tampa, Fla., is a privately held innovative biotechnology company focused on the discovery of novel classes of therapeutic candidates. Magellan is using its integrated platform technologies to isolate and identify new biologically active compounds. The company believes that its library of marine microbes will be the next source of drug discovery for the pharmaceutical industry. Magellan aims to develop and optimize drug candidates to treat cancer, infectious diseases, and inflammation. For additional information, please refer to the company’s web site at www.magellanbioscience.com.
About the University of South Florida:
The University of South Florida is among the nation's top 63 public research universities and one of 76 community engaged universities as designated by the Carnegie Foundation for the Advancement of Teaching. USF was awarded more than $310 million in research contracts and grants last year. The University offers 217 degree programs at the undergraduate, graduate, specialty and doctoral levels, including the doctor of medicine. The University has a $1.6 billion annual budget, an annual economic impact of $3.2 billion, and serves 44,038 students on campuses in Tampa, St. Petersburg, Sarasota-Manatee and Lakeland. USF is a member of the Big East Athletic Conference.
Contact:
Todd R. Daviau, Ph.D.,
Magellan BioScience Group, Inc.
6101 Johns Road, Suite 8
Tampa, FL 33634 USA
Phone: (727) 865-1300
Fax: (813) 514-9401
Email: info@magellanbioscience.com
http://www.magellanbioscience.com
###
This collaboration will bring together Magellan’s unique collection of marine-derived microorganisms and their natural product chemistry expertise with Dr. Kyle’s anti-malaria screening technologies, and Dr. Baker’s natural product discovery expertise. The Magellan-USF team will characterize lead candidates from Magellan’s collection by using bioassays and will optimize novel chemicals into preclinical drug candidates. Magellan’s expertise in various chemistry technologies will stimulate and accelerate early discovery efforts.
“We are excited to initiate this drug discovery collaboration with the University of South Florida that will further validate our capabilities as a provider of novel small molecules and develop Magellan into a preferred First Class Drug Discovery Company,” said Dr. Todd R. Daviau, CEO of Magellan. “USF’s scientific and technological approach powered by their highly qualified and organized research team constitutes a significant opportunity for the discovery and development of new anti-malaria candidates.”
“Malaria is a major public health threat, with over 2 million children dying of the disease every year in Africa,” said Dr. Dennis Kyle, Professor of Global Health. “New drugs are urgently needed to combat multi-drug resistant malaria.”
About Magellan:
Magellan BioScience Group, Inc., based in Tampa, Fla., is a privately held innovative biotechnology company focused on the discovery of novel classes of therapeutic candidates. Magellan is using its integrated platform technologies to isolate and identify new biologically active compounds. The company believes that its library of marine microbes will be the next source of drug discovery for the pharmaceutical industry. Magellan aims to develop and optimize drug candidates to treat cancer, infectious diseases, and inflammation. For additional information, please refer to the company’s web site at www.magellanbioscience.com.
About the University of South Florida:
The University of South Florida is among the nation's top 63 public research universities and one of 76 community engaged universities as designated by the Carnegie Foundation for the Advancement of Teaching. USF was awarded more than $310 million in research contracts and grants last year. The University offers 217 degree programs at the undergraduate, graduate, specialty and doctoral levels, including the doctor of medicine. The University has a $1.6 billion annual budget, an annual economic impact of $3.2 billion, and serves 44,038 students on campuses in Tampa, St. Petersburg, Sarasota-Manatee and Lakeland. USF is a member of the Big East Athletic Conference.
Contact:
Todd R. Daviau, Ph.D.,
Magellan BioScience Group, Inc.
6101 Johns Road, Suite 8
Tampa, FL 33634 USA
Phone: (727) 865-1300
Fax: (813) 514-9401
Email: info@magellanbioscience.com
http://www.magellanbioscience.com
###
Contact
Magellan BioScience Group, Inc.
Todd R. Daviau
727-865-1300
www.magellanbioscience.com
Todd R. Daviau
727-865-1300
www.magellanbioscience.com
Contact
Categories